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DOI 10.1016/j.chom.2010.01.003Acute respiratory viral infections cause
significant morbidity and mortality in the
United States and worldwide. Unfortu-
nately, clinicians do not currently have
practical means to make a timely and
accurate diagnosis of acute viral respira-
tory infections, leading to unnecessary
antibiotic treatment that increases health-
care costs and facilitates development of
antibiotic resistance. In a recent break-
through paper in Cell Host & Microbe,
Zaas et al. (2009) provided a novel
approach for diagnosis of acute respira-
tory infections based on microarray
gene-expression profiles of blood from
infected and uninfected subjects. They
developed an ‘‘acute respiratory viral
response,’’ a 30-gene panviral signature
that can accurately diagnose symptom-
atic subjects (with influenza A, HRV, and
RSV) from uninfected individuals and vali-
dated this signature using data from an
independent study that contained influ-
enza A patients and healthy controls
(Ramilo et al., 2007). Overall, the study
of Zaas et al. made a significant contribu-
tion toward improved diagnosis of infec-
tious diseases. In this brief communica-
tion, we first propose several ways to
improve the analysis that led to develop-
ment of the 30-gene panviral signature
and then provide an example of how the
new analysis protocol can lead to an
improved molecular signature.
We suggest several approaches to
improve the analysis protocol that led to
discovery of the acute respiratory viral
response signature. First, to obtain an
unbiased estimate of predictive accuracy,
genes should be selected using the
training set of subjects as opposed to
selecting genes from the entire data set
as was done in the study of Zaas et al.
(2009). The latter gene selection proce-
dure is known to typically lead to over-100 Cell Host & Microbe 7, February 18, 2010optimistic predictive accuracy estimates.
Second, the cross-validation procedure
employed by Zaas et al. should be modi-
fied to prohibit the use of samples from
the same subjects both for developing
signature and estimating its predictive
accuracy, as this is another potential
source of over-optimism. Third, the em-
ployed factor analysis-based gene selec-
tion method does not control for false
discovery rate and may output redundant
genes that are not located in the pathway
causing the phenotype (i.e., they may not
allow proper mechanistic interpretation
and, e.g., may be ‘‘passenger genes’’).
In addition, the choice of 30 genes used
by Zaas et al. is arbitrary. There exist
methods that circumvent all these issues
(Aliferis et al., 2010). Fourth, the indepen-
dent data set of Ramilo et al. (2007)
used for validation of the signature does
not contain data for two out of three
viruses (RSV and HRV) and originates
mostly from pediatric subjects, whereas
the data used for development of the
30-gene panviral signature spanned all
three viruses and is based on adult
subjects. Therefore, more similar data
sets should be sought for ‘‘apples-to-
apples’’ validation. Finally, fifth, it would
be useful to not only show the existence
of a single signature to discriminate
symptomatic subjects from uninfected
individuals, but also to seek all possible
maximally predictive signatures of the
phenotype that do not contain redundant
genes. Such analysis allows improvement
in the discovery of the underlying biolog-
ical mechanisms by not missing genes
that are implicated mechanistically in the
disease processes, and computationally
efficient methods have been recently
introduced to solve this problem (Statni-
kov, 2008). In summary, we suspect that
the procedures employed in Zaas et al.ª2010 Elsevier Inc.to discover genes and signatures likely
provide redundant genes, over-optimistic
estimates of predictive accuracy, and
biologically ‘‘false positive’’ (i.e., noncau-
sative) and ‘‘false negative’’ (i.e., biologi-
cally significant but overlooked) genes.
Below we provide an example of how
a causal graph-based analysis can lead
to a more parsimonious signature that
can predict phenotype with high accuracy
and eliminates known sources of over-
optimistic estimation of predictive accu-
racy. We undertook an additional analysis
of the gene-expression data of Zaas et al.
To select genes, we used HITON-PC, a
supervised multivariate biomarker dis-
covery method (Aliferis et al., 2010). This
method is designed to discover local
pathway members around the response
variable of interest. In addition, the genes
selected under certain broad assump-
tions exhibit maximal predictive accuracy
for the data set at hand combined with
maximum parsimony, beyond which pre-
dictive accuracy is compromised. Once
the genes were selected, we applied
support vector machine (SVM) classifiers
to develop molecular signatures. These
classifiers are robust even with the high
variable-to-sample ratio, they can learn
efficiently complex classification func-
tions, they employ powerful regularization
principles to avoid overfitting, and they
are fairly insensitive to the large number
of irrelevant variables. In order to obtain
an unbiased estimate of predictive accu-
racy that will hold in future applications
of signatures to unseen patients, gene
selection, and development of molecular
signatures was performed by repeated
10-fold cross-validation. Finally, to ensure
signature reproducibility, we applied the
procedure for assessing statistical signifi-
cance of multivariate signatures. This
procedure involves creating 1000
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labels and building molecular signatures
and estimating their predictive accuracy
for the permuted sample labels (Aliferis
et al., 2009b).
Using the original data set of Zaas et al.,
we applied the HITON-PC method for
biomarker discovery and fitted SVM
models to diagnose symptomatic sub-
jects from uninfected individuals using
only training sets of samples within the
repeated 10-fold cross-validation pro-
tocol. Since there are two samples for
each subject who remained asymptom-
atic (one from baseline and another one
from peak time), we randomly assigned
these samples together either to the
training or to the testing set, thus avoiding
situations where we will train and test on
the same subjects. The above procedure
yields an unbiased cross-validated esti-
mate of predictive accuracy, 0.94 AUC
(95% confidence interval [0.89; 0.99]
AUC). On average HITON-PC selected
ten genes depending on the training set
of cross-validation. Genes that were
selected by HITON-PC in more than
20% of the training sets are listed in
Figure S1A. Next, HITON-PC and SVM
were applied to the data for all samples,
resulting in a 12-gene panviral signature
(see Figure S1B). Notice that all these
12 genes except for DEGS1 were also
among the most frequently selected by
HITON-PC during cross-validation. This
12-gene signature yields 0.99 AUC (95%
confidence interval [0.98; 1.00] AUC) in
the data of (Ramilo et al., 2007), which is
statistically indistinguishable from thepre-
dictive accuracy of the 30-gene signature
of Zaas et al.
Genes that participate in the 12-gene
signature discovered by HITON-PC are
the following: GRAMD1C, OSBPL10,
ID3, IGHD, C13orf18,MS4A1, RAPGEF6,
GTF2I, DEGS1, FCGR1B, IFI44L, and
RSAD2. Only two of these genes (IFI44L
and RSAD2) are among the original
group of 30 genes that were included in
the panviral signature of Zaas et al.
FCGR1B was not reported by Zaas et al.
in the panviral signature, but was found
in the RSV-specific signature. Among
ten unique genes in the panviral signature
reported here, the following genes are
directly involved in immune responses:GTF2I, DEGS1, ID3, IGHD, FCGR1B,
and MS4A1. GTF2I or general tran-
scription factor II-i is involved in T cell
activation and proliferation as well as
regulation of the immunoglobulin pro-
moter (Sacrista´n et al., 2009; Tantin
et al., 2004). DEGS1, the degenerative
spermatocyte homolog 1, is upregulated
in natural killer cells, which are an impor-
tant component of the innate immune
response (Dybkaer et al., 2007). ID3 or
inhibitor of DNA binding 3 promotes
development of gD T cells, enabling
them to become competent to produce
interferon-g, and also plays an integral
role in a mouse model of the autoimmune
disease, Sjogren’s syndrome (Lauritsen
et al., 2009; Li et al., 2004). IGHD or immu-
noglobulin heavy chain D is produced
by B cells, although the role of IgD is not
clearly defined in comparison to the other
immunoglobulins. FCGR1B encodes a
receptor for the constant region of IgG. It
is expressed onmyeloid cells and upregu-
lated by interferon-g (Eichbaum et al.,
1994). MS4A1 encodes CD20, which is
expressed on the plasma membrane of
mature B cells. To summarize, 8 of the
12 genes that differentiate symptomatic
from asymptomatic individuals are di-
rectly involved in immune responses.
Further, four of these genes (IFI44L,
RSAD2, ID3, and FCGR1B), are either
upstream or downstream of interferon
production, which is widely involved in
the immune response to viral infection.
As mentioned above, HITON-PC dis-
covers genes in the local pathway of the
response variable of interest under the
assumptions stated (Aliferis et al., 2010).
Below we provide an interpretation of
the HITON-PC results in light of possible
violations of its key assumptions in the
data set of Zaas et al. First, because of
small sample size, some statistical tests
of conditional independence may be
underpowered, which leads to false nega-
tives in the output of the method. Notice
that because the discovered genes
provide a very high value of predictive
accuracy (0.94 AUC), any such false
negatives are fairly insignificant because
they can uniquely account for only 0.06
AUC (= 1.0–0.94). Second, because of
the possible presence of hidden variables
in the local pathway of the responseCell Host & Microbe 7,variable (i.e., not anywhere in the net-
work), some of the genes discovered by
HITON-PC may be false positives (i.e.,
confounded by local unmeasured vari-
ables). Given that the output of the
method contains only 12 genes, further
validation of their mechanistic role is
much easier than working with substan-
tially larger gene lists returned by other
methods.
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